Heather Jacene, MD
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
Phone: (617) 632-3767
Fax: (617) 632-3581
Heather Jacene, MD
Dana-Farber Cancer Institute
EDUCATIONAL TITLES
Publications from Harvard Catalyst Profiles
- Trinh K, Chow DZ, Park H, Habib U, Offit L, Franquet E, Almeida RR, Wang Y, Borges N, Jamal F, Jacene HA, Heidari P, Ng TSC. Evaluating the added value of concurrent contrast-enhanced diagnostic CT for PSMA-PET/CT Interpretation. Acad Radiol 2024. PubMed
- Morgan TM, Boorjian SA, Buyyounouski MK, Chapin BF, Chen DYT, Cheng HH, Chou R, Jacene HA, Kamran SC, Kim SK, Kirkby E, Luckenbaugh AN, Nathanson BJ, Nyame YA, Posadas EM, Tran PT, Chen RC. Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part II: Treatment Delivery for Non-metastatic Biochemical Recurrence After Primary Radical Prostatectomy. J Urol 2024; 211:518-525. PubMed
- Morgan TM, Boorjian SA, Buyyounouski MK, Chapin BF, Chen DYT, Cheng HH, Chou R, Jacene HA, Kamran SC, Kim SK, Kirkby E, Luckenbaugh AN, Nathanson BJ, Nyame YA, Posadas EM, Tran PT, Chen RC. Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part III: Salvage Therapy After Radiotherapy or Focal Therapy, Pelvic Nodal Recurrence and Oligometastasis, and Future Directions. J Urol 2024; 211:526-532. PubMed
- Morgan TM, Boorjian SA, Buyyounouski MK, Chapin BF, Chen DYT, Cheng HH, Chou R, Jacene HA, Kamran SC, Kim SK, Kirkby E, Luckenbaugh AN, Nathanson BJ, Nyame YA, Posadas EM, Tran PT, Chen RC. Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part I: Introduction and Treatment Decision-Making at the Time of Suspected Biochemical Recurrence after Radical Prostatectomy. J Urol 2024; 211:509-517. PubMed
- Choudhury AD, Kwak L, Cheung A, Allaire KM, Marquez J, Yang DD, Tripathi A, Kilar JM, Flynn M, Maynard B, Reichel R, Pace AF, Chen BK, Van Allen EM, Kilbridge K, Wei XX, McGregor BA, Pomerantz MM, Bhatt RS, Sweeney CJ, Bubley GJ, Jacene HA, Taplin ME, Huang FW, Harshman LC, Fong L. Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer. Cancer Immunol Res 2024. PubMed
- Vaz N, Dietsche E, Mooney MA, Choudhury AD, Jacene HA. Late Subacute Cerebral Hematoma Mimicking a Metastasis on PSMA PET/CT. Clin Nucl Med 2024; 49:e70-e72. PubMed
- Litton JK, Regan MM, Pusztai L, Rugo HS, Tolaney SM, Garrett-Mayer E, Amiri-Kordestani L, Basho RK, Best AF, Boileau JF, Denkert C, Foster JC, Harbeck N, Jacene HA, King TA, Mason G, O'Sullivan CC, Prowell TM, Richardson AL, Sepulveda KA, Smith ML, Tjoe JA, Turashvili G, Woodward WA, Butler LP, Schwartz EI, Korde LA. Standardized Definitions for Efficacy End Points in Neoadjuvant Breast Cancer Clinical Trials: NeoSTEEP. J Clin Oncol 2023. PubMed
- Vaz N, Franquet E, Heidari P, Chow DZ, Jacene HA, Ng TSC. COVID-19: Findings in nuclear medicine from head to toe. Clin Imaging 2023; 99:10-18. PubMed
- McCall KC, Liu M, Cheng SC, Abbott A, Dubey S, Young D, Johnston M, Van den Abbeele AD, Overmoyer B, Jacene H. Report on the PET/CT Image-Based Radiation Dosimetry of [F]FDHT in Women, a Validated Imaging Agent with New Applications for Evaluation of Androgen Receptor Status in Women with Metastatic Breast Cancer. J Nucl Med Technol 2023. PubMed
- Merryman RW, Redd RA, Taranto E, Ahmed G, Jeter E, McHugh KM, Brown JR, Crombie JL, Davids MS, Fisher DC, Freedman AS, Jacobsen ED, Jacobson CA, Kim AI, LaCasce AS, Ng SY, Odejide OO, Parry EM, Jacene H, Park H, Dahi PB, Nieto Y, Joyce R, Chen YB, Shipp MA, Herrera AF, Armand P. Minimal residual disease in patients with diffuse large B-cell lymphoma undergoing autologous stem cell transplantation. Blood Adv 2022. PubMed
- Wrenn SM, Moore AL, Shah HJ, Barletta JA, Vaidya A, Kilbridge KL, Doherty GM, Jacene HA, Nehs MA. Higher SUV on FDG-PET is associated with shorter survival in adrenocortical carcinoma. Am J Surg 2022. PubMed
- Kako B, Dong JW, An BP, McLoud TC, Durfee SM, Jacene HA, Chow DZ, Wang Y, Hyun H, Ng TSC. Key Factors to Attract More U.S. Diagnostic Radiology Residents into the Field of Nuclear Medicine and Molecular Imaging: A National Survey. Acad Radiol 2022. PubMed
- Sakellis CG, Jacene HA. Imaging for Radiation Planning in Breast Cancer. Semin Nucl Med 2022. PubMed
- Ng TSC, Hu H, Kronister S, Lee C, Li R, Gerosa L, Stopka SA, Burgenske DM, Khurana I, Regan MS, Vallabhaneni S, Putta N, Scott E, Matvey D, Giobbie-Hurder A, Kohler RH, Sarkaria JN, Parangi S, Sorger PK, Agar NYR, Jacene HA, Sullivan RJ, Buchbinder E, Mikula H, Weissleder R, Miller MA. Overcoming differential tumor penetration of BRAF inhibitors using computationally guided combination therapy. Sci Adv 2022; 8:eabl6339. PubMed
- Shah H, Wang Y, Cheng SC, Gunasti L, Chen YH, Lako A, Guenette J, Rodig S, Jo VY, Uppaluri R, Haddad R, Schoenfeld JD, Jacene HA. Use of Fluoro-[18F]-Deoxy-2-D-Glucose Positron Emission Tomography/Computed Tomography to Predict Immunotherapy Treatment Response in Patients With Squamous Cell Oral Cavity Cancers. JAMA Otolaryngol Head Neck Surg 2022; 148:268-276. PubMed
- Hughes NM, Hammer MM, Awad MM, Jacene HA. Radiation Recall Pneumonitis on FDG PET/CT Triggered by COVID-19 Vaccination. Clin Nucl Med 2021. PubMed
- Hughes NM, Jacene HA. PET Imaging for Hematologic Malignancies. Radiol Clin North Am 2021; 59:705-723. PubMed
- Wahl RL, Frey EC, Jacene HA, Kahl BS, Piantadosi S, Bianco JA, Hammes RJ, Jung M, Kasecamp W, He B, Sgouros G, Flinn IW, Swinnen LJ. Prospective SPECT-CT Organ Dosimetry-Driven Radiation-Absorbed Dose Escalation Using the In-111 (In)/Yttrium 90 (Y) Ibritumomab Tiuxetan (Zevalin) Theranostic Pair in Patients with Lymphoma at Myeloablative Dose Levels. Cancers (Basel) 2021. PubMed
- Jacene HA, Liu M, Cheng SC, Abbott A, Dubey S, McCall K, Young D, Johnston M, Van den Abbeele AD, Overmoyer B. Imaging Androgen Receptors in Breast Cancer with F-fluoro-5α-dihydrotestosterone-PET: A Pilot Study. J Nucl Med 2021. PubMed
- Dabiri BE, Jacene HA. Intercostal Brown Adipose Tissue on FDG PET/CT. AJR Am J Roentgenol 2021. PubMed
- Jacene HA. FDG PET for Assessment of Autologous Stem Cell Transplantation. Semin Nucl Med 2021. PubMed
- Hurwitz M, Buscombe JR, Jacene HA, Klitzke AK, Lamonica D, Lu Y, Pryma DA, Rohren EM, Speer TW, Subramaniam RM, Thompson HM, Tomblyn MB, Wong WW, Xiao Y, Banks KP, Brown RKJ. ACR-ACNM-ASTRO-SNMMI Practice Parameter for the Performance of Therapy With Radium-223. Am J Clin Oncol 2020. PubMed
- Jacene HA, DiPiro PJ, Bellon J, Hu J, Cheng SC, Warren L, Schlosnagle E, Nakhlis F, Rosenbluth JM, Yeh E, Overmoyer B. Discrepancy between FDG-PET/CT and contrast-enhanced CT in the staging of patients with inflammatory breast cancer: implications for treatment planning. Breast Cancer Res Treat 2020; 181:383-390. PubMed
- Merryman RW, Edwin N, Redd R, Bsat J, Chase M, LaCasce A, Freedman A, Jacobson C, Fisher D, Ng S, Crombie J, Kim A, Odejide O, Davids MS, Brown JR, Jacene H, Cashen A, Bartlett NL, Mehta-Shah N, Ghobadi A, Kahl B, Joyce R, Armand P, Jacobsen E. Rituximab/bendamustine and rituximab/cytarabine induction therapy for transplant-eligible mantle cell lymphoma. Blood Adv 2020; 4:858-867. PubMed
- Thomas R, Shinagare AB, Rosenthal MH, Lee B, Jacene HA, Johnston MA, Overmoyer BA. Computed tomographic assessment of lean body mass in patients on selective androgen receptor modulator. Clin Imaging 2020; 59:100-103. PubMed
- Nakhlis F, Regan MM, Chun YS, Dominici LS, Caterson S, Bellon JR, Warren L, Yeh ED, Jacene HA, King TA, Overmoyer B. Patterns of breast reconstruction in patients diagnosed with inflammatory breast cancer: The Dana-Farber Cancer Institute's Inflammatory Breast Cancer Program experience. Breast J 2019. PubMed
- Morris MJ, Loriot Y, Sweeney CJ, Fizazi K, Ryan CJ, Shevrin DH, Antonarakis ES, Pandit-Taskar N, Deandreis D, Jacene HA, Vesselle H, Petrenciuc O, Lu C, Carrasquillo JA, Higano CS. Radium-223 in combination with docetaxel in patients with castration-resistant prostate cancer and bone metastases: a phase 1 dose escalation/randomised phase 2a trial. Eur J Cancer 2019; 114:107-116. PubMed
- Ng TSC, Sakellis CG, Jacene HA. Extraosseous Colonic Uptake of 99mTc-MDP Associated With Iodinated Contrast CT. Clin Nucl Med 2019; 44:414-416. PubMed
- Jacene HA, Youn T, DiPiro PJ, Hu J, Cheng SC, Franchetti Y, Shah H, Bellon JR, Warren L, Schlosnagle E, Nakhlis F, Rosenbluth J, Yeh E, Overmoyer B, . Metabolic Characterization of Inflammatory Breast Cancer With Baseline FDG-PET/CT: Relationship With Pathologic Response After Neoadjuvant Chemotherapy, Receptor Status, and Tumor Grade. Clin Breast Cancer 2018. PubMed
- Shah S, Luke JJ, Jacene HA, Chen T, Giobbie-Hurder A, Ibrahim N, Buchbinder EL, McDermott DF, Flaherty KT, Sullivan RJ, Lawrence DP, Ott PA, Hodi FS. Results from phase II trial of HSP90 inhibitor, STA-9090 (ganetespib), in metastatic uveal melanoma. Melanoma Res 2018. PubMed
- Abbott A, Sakellis CG, Andersen E, Kuzuhara Y, Gilbert L, Boyle K, Kulke MH, Chan JA, Jacene HA, Van den Abbeele AD. Guidance on Lu-DOTATATE Peptide Receptor Radionuclide Therapy from the Experience of a Single Nuclear Medicine Division. J Nucl Med Technol 2018; 46:237-244. PubMed
- McKay RR, Bossé D, Gray KP, Michaelson MD, Krajewski K, Jacene HA, Walsh M, Bellmunt J, Pomerantz M, Harshman LC, Choueiri TK. Radium-223 Dichloride in Combination with Vascular Endothelial Growth Factor-Targeting Therapy in Advanced Renal Cell Carcinoma with Bone Metastases. Clin Cancer Res 2018. PubMed
- Rosica D, Cheng SC, Hudson M, Sakellis C, Van den Abbeele AD, Kim CK, Jacene HA. Effects of hyperglycemia on fluorine-18-fluorodeoxyglucose biodistribution in a large oncology clinical practice. Nucl Med Commun 2018; 39:417-422. PubMed
- Kamran SC, Jacene HA, Chen YH, Mauch PM, Ng AK. Clinical outcome of patients with early stage favorable Hodgkin lymphoma treated with ABVD × two cycles followed by FDG-PET/CT restaging and 20 Gy of involved-site radiotherapy. Leuk Lymphoma 2017. PubMed
- Nakhlis F, Regan MM, Warren LE, Bellon JR, Hirshfield-Bartek J, Duggan MM, Dominici LS, Golshan M, Jacene HA, Yeh ED, Mullaney EE, Overmoyer B. The Impact of Residual Disease After Preoperative Systemic Therapy on Clinical Outcomes in Patients with Inflammatory Breast Cancer. Ann Surg Oncol 2017. PubMed
- Alabed YZ, Cheng SC, Mudge C, Sakellis C, Van den Abbeele AD, Campos SM, Jacene HA. Surveillance Imaging in Patients With Endometrial Cancer in First Remission. 2017. PubMed
- O JH, Jacene HA, Luber B, Wang H, Leal J, Huynh MH, Wahl RL. Quantitation of cancer treatment response by FDG PET/CT: multi-center assessment of measurement variability. J Nucl Med 2017. PubMed
- Cheson BD, Ansell S, Schwartz L, Gordon LI, Advani R, Jacene HA, Hoos A, Barrington SF, Armand P. Refinement of the Lugano classification response criteria for lymphoma in the era of immunomodulatory therapy. Blood 2016. PubMed
- McKay RR, Jacobus S, Fiorillo M, Ledet EM, Cotogna PM, Steinberger AE, Jacene HA, Sartor O, Taplin ME. Radium-223 Use in Clinical Practice and Variables Associated With Completion of Therapy. Clin Genitourin Cancer 2016. PubMed
- Van den Abbeele AD, Krajewski KM, Tirumani SH, Fennessy FM, DiPiro PJ, Nguyen QD, Harris GJ, Jacene HA, Lefever G, Ramaiya NH. Cancer Imaging at the Crossroads of Precision Medicine: Perspective From an Academic Imaging Department in a Comprehensive Cancer Center. J Am Coll Radiol 2016; 13:365-71. PubMed
- Warren LE, Guo H, Regan MM, Nakhlis F, Yeh ED, Jacene HA, Hirshfield-Bartek J, Overmoyer BA, Bellon JR. Inflammatory Breast Cancer: Patterns of Failure and the Case for Aggressive Locoregional Management. Ann Surg Oncol 2015. PubMed
- Warren LE, Guo H, Regan MM, Nakhlis F, Yeh ED, Jacene HA, Hirshfield-Bartek J, Overmoyer BA, Bellon JR. Inflammatory breast cancer and development of brain metastases: risk factors and outcomes. Breast Cancer Res Treat 2015; 151:225-32. PubMed
- Tirumani SH, LaCasce AS, Jacene HA. Role of 2-Deoxy-2-[18F]-fluoro-d-glucose-PET/Computed Tomography in Lymphoma. PET Clin 2015; 10:207-25. PubMed
- Mandelker D, Dal Cin P, Jacene HA, Armand P, Stone RM, Lindeman NI. Refractory myeloid sarcoma with a FIP1L1-PDGFRA rearrangement detected by clinical high throughput somatic sequencing. Exp Hematol Oncol 2015; 4:30. PubMed
- Abi-Ghanem AS, McGrath MA, Jacene HA. Radionuclide therapy for osseous metastases in prostate cancer. Semin Nucl Med 2015; 45:66-80. PubMed
- Pyo J, Won Kim K, Jacene HA, Sakellis CG, Brown JR, Van den Abbeele AD. End-therapy positron emission tomography for treatment response assessment in follicular lymphoma: a systematic review and meta-analysis. Clin Cancer Res 2013; 19:6566-77. PubMed
- Hawryluk EB, O'Regan KN, Sheehy N, Guo Y, Dorosario A, Sakellis CG, Jacene HA, Wang LC. Positron emission tomography/computed tomography imaging in Merkel cell carcinoma: a study of 270 scans in 97 patients at the Dana-Farber/Brigham and Women's Cancer Center. J Am Acad Dermatol 2013. PubMed
- Halasz LM, Jacene HA, Catalano PJ, Van den Abbeele AD, Lacasce A, Mauch PM, Ng AK. Combined modality treatment for PET-positive non-Hodgkin lymphoma: favorable outcomes of combined modality treatment for patients with non-Hodgkin lymphoma and positive interim or postchemotherapy FDG-PET. Int J Radiat Oncol Biol Phys 2012; 83:e647-54. PubMed
- Messersmith WA, Jimeno A, Jacene H, Zhao M, Kulesza P, Laheru DA, Kahn Y, Spira A, Dancey J, Iacobuzio-Donahue C, Donehower RC, Carducci M, Rudek MA, Hidalgo M. Phase I trial of oxaliplatin, infusional 5-fluorouracil, and leucovorin (FOLFOX4) with erlotinib and bevacizumab in colorectal cancer. Clin Colorectal Cancer 2010; 9:297-304. PubMed
- Goudarzi B, Jacene HA, Wahl RL. Measuring the "unmeasurable": assessment of bone marrow response to therapy using FDG-PET in patients with lymphoma. Acad Radiol 2010; 17:1175-85. PubMed
- Jacene HA, Leboulleux S, Baba S, Chatzifotiadis D, Goudarzi B, Teytelbaum O, Horton KM, Kamel I, Macura KJ, Tsai HL, Kowalski J, Wahl RL. Assessment of interobserver reproducibility in quantitative 18F-FDG PET and CT measurements of tumor response to therapy. J Nucl Med 2009; 50:1760-9. PubMed
- Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors. J Nucl Med 2009; 50 Suppl 1:122S-50S. PubMed
- Lyford-Pike S, Ha PK, Jacene HA, Saunders JR, Tufano RP. Limitations of PET/CT in determining need for neck dissection after primary chemoradiation for advanced head and neck squamous cell carcinoma. 2009; 71:251-6. PubMed
- Yeh ED, Jacene HA, Bellon JR, Nakhlis F, Birdwell RL, Georgian-Smith D, Giess CS, Hirshfield-Bartek J, Overmoyer B, Van den Abbeele AD. What radiologists need to know about diagnosis and treatment of inflammatory breast cancer: a multidisciplinary approach. Radiographics ; 33:2003-17. PubMed
- Kwak JJ, Tirumani SH, Van den Abbeele AD, Koo PJ, Jacene HA. Cancer immunotherapy: imaging assessment of novel treatment response patterns and immune-related adverse events. Radiographics ; 35:424-37. PubMed